Adaptimmune Therapeutics Plc - ADR
NASDAQ:ADAP 3:59:51 PM EDT
| Market Cap (Intraday) | 276.80M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.69 |
| 50-Day MA | $1.64 |
| 200-Day MA | $3.15 |
Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX
United Kingdom
Phone: +44.1235.430000
Number of Employees: 494
Description
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.